Supported by Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC
Expert PerspectivesTM: The Illusive Irritable Bowel Syndrome with Diarrhea–Targeting Etiology with Emerging Therapies will provide practical guidance on the optimal clinical use of emerging agents and evolving treatment paradigms in IBS-D. This activity will highlight new therapies and how to use them in combination with other supportive therapies; diagnosing underlying etiology; and a review of therapies under investigation.
This online educational activity is designed to meet the educational needs of internal medical physicians, primary care physicians, gastroenterologists, and other healthcare professionals (physician assistants, physicians-in-training, nurses, pharmacists, etc.) who are involved and/or interested in the treatment of patients with IBS-D.
Upon successful completion of the recommended education, participants will be better able to:
Assess the pathophysiology of IBS-D, the various etiologies that may contribute to the disease, and how current therapies target these underlying causes
Assess current diagnostic criteria and testing options for IBS-D
Evaluate the latest therapies for IBS-D, their mechanism of action, and how they should be used in clinical practice
Evaluate the use of combination therapy in IBS-D
Brian E. Lacy, MD, PhD Dartmouth-Hitchcock Medical Center Lebanon, NH
Baharak Moshiree, MD, MS University of Miami Health System Miami, FL
Nicholas J. Talley, MD, PhD, AGAF Mayo Clinic Rochester, MN
Faculty Disclosures: All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
Brian E. Lacy, MD, PhD: Allergan(2), Ironwood(2), Salix(2).
Nicholas J. Talley, MD, PhD, AGAF: Abbott Pharmaceuticals(1), Adelphi values(2), Allergens PLC(2), GI Therapies(1,2), Janssen(1), Prometheus(1), Pfizer (at mayo Clinic)(1), Rome Foundation(1), Salix (at Mayo Clinic)(1), Yuhan(2).
Accredited Provider Disclosure
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options, clinically relevant and evidence-based recommendations, and avoid bias towards any specific commercial product and/or service.
Publishing Staff Disclosures
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following:
Chris Bolwell, Chief Operating Officer, owns shares of stock of GlaxoSmithKline.
AMA PRA Category 1 Credit(s)TM
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this enduring educational activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hour of Category 1 credit for completing this program.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Disclosure of Unlabled Use
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your account's CME History, which you can access at any time.